Management of V600E and V600K BRAF-Mutant Melanoma.

ABSTRACT:

Opinion statement

The optimal management of advanced stage BRAF-mutated melanoma is widely debated and complicated by the availability of several different regimens that significantly improve outcomes but have not been directly compared. While there are many unanswered questions relevant to this patient population, the major uncertainty in current practice is the choice between BRAF/MEK inhibitors or immunotherapy for those with previously untreated metastatic or high-risk disease. Decisions regarding first line therapy should include consideration of patient preference as well as the presence of symptomatic metastatic disease and degree of comorbidity, particularly secondary to any history of severe auto-immune disorder.BRAF/MEK inhibitors have a high response rate and rapid onset

SUBMITTER: Haugh AM 

PROVIDER: S-EPMC10176035 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature